Actuate Net Income From Continuing Ops from 2010 to 2026
| ACTU Stock | 5.45 0.06 1.11% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -24.6 M | Current Value -25.8 M | Quarterly Volatility 2.4 M |
Check Actuate Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Actuate Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 191.9 K, Interest Income of 220.7 K or Depreciation And Amortization of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.4 K. Actuate financial statements analysis is a perfect complement when working with Actuate Therapeutics Valuation or Volatility modules.
Actuate | Net Income From Continuing Ops | Build AI portfolio with Actuate Stock |
Latest Actuate Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Actuate Therapeutics Common over the last few years. It is Actuate Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Actuate Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Actuate Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (21,437,858) | |
| Coefficient Of Variation | (11.37) | |
| Mean Deviation | 1,955,288 | |
| Median | (20,159,401) | |
| Standard Deviation | 2,436,669 | |
| Sample Variance | 5.9T | |
| Range | 7.1M | |
| R-Value | (0.72) | |
| Mean Square Error | 3.1T | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | (346,729) | |
| Total Sum of Squares | 95T |
Actuate Net Income From Continuing Ops History
About Actuate Therapeutics Financial Statements
Actuate Therapeutics shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Actuate Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Actuate Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Actuate Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -24.6 M | -25.8 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Actuate Stock Analysis
When running Actuate Therapeutics' price analysis, check to measure Actuate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Actuate Therapeutics is operating at the current time. Most of Actuate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Actuate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Actuate Therapeutics' price. Additionally, you may evaluate how the addition of Actuate Therapeutics to your portfolios can decrease your overall portfolio volatility.